Back to Awarded Treatment Trials


Awarded Trial: 09T-1281

Grant ID

09T-1281

Illness

Schizophrenia

Primary Drug/Intervention

Omega-3 fatty acids (EPA 2g/day and DHA 1g/day)

Primary Dosage

3 g/day

Secondary Drug Intervention

Alpha-lipoic acid

Secondary Dosage

300 mg/day

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Emsley

Sample Size

80

Duration of Study Period for Each Subject

3 years

Outcome Measurements

N/A

Results

Patients who were successfully treated for 2-3 years after a first-episode of schizophrenia, schizo-affective or schizophreniform disorder were randomized to receive omega-3 polyunsaturated fatty acids (รน-3 PUFAs) and alpha-lipoic acid (รก-LA) or placebo. Recruitment was terminated prematurely due to high relapse rates in both treatment groups. Thirty-three patients were randomized; of these, 19/21 receiving treatment drug relapsed, and 9/12 receiving placebo relapsed. There was no significant difference between the mean time to relapse and relapse symptom severity between the two groups.

Publication

N/A

Link

N/A

PI Name

Robin Emsley

Degree

MD

Center

Psychiatry

Institution

University of Stellenbosch

Address

PO Box 19063, Tygerberg

City or Town

Cape Town

State or Province

Western Cape

Zip or Postal Code

7505

Country

South Africa

Email Address

rae@sun.ac.za